Study of mirtazapine antidepressant effects in rats

International Journal of Neuropsychopharmacology

Volumn 8, Issue 3, 2005, Pages 369-379

  Rauggi, Riccardo ^a   Cassanelli, Anna ^a   Raone, Anna ^a   Tagliamonte, Alessandro ^a   Gambarana, Carla ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

adrenergic receptors; 5 HT1A receptors; Animal models; Appetitive behaviour; Escape deficit; Stress

Indexed keywords

ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; MIRTAZAPINE; SEROTONIN 1A ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ACTIVITY; DRUG EFFICACY; FEEDING BEHAVIOR; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT; STRESS;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ESCAPE REACTION; MALE; MIANSERIN; MOTOR ACTIVITY; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CELL SURFACE; TIME FACTORS;

EID: 22344441540     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145705005146     Document Type: Article

References (34)

1. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn Schmiedebergs Archives of Pharmacology 347, 353-362.
2. Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A (2002). Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. Journal of Neuroscience 22, 6766-6772.
3. 1A-agonistic effects of the new antidepressant mirtazapine. Psychopharmacology 133, 275-282.
4. 1A receptors in rat brain. Neuropharmacology 44, 93-101.
5. D'Amour FE, Smith DL (1941). A method for determining loss of pain sensation. Journal of Pharmacology and Experimental Therapeutics 72, 74-79.
6. Dazzi L, Spiga F, Pira L, Ladu S, Vacca G, Rivano A, Jentsch JD, Biggio G (2001). Inhibition of stress- or anxiogenic-drug-induced increases in dopamine release in the rat prefrontal cortex by long-term treatment with antidepressant drugs. Journal of Neurochemistry 76, 1212-1220.
7. De Boer T (1996). The pharmacologic profile of mirtazapine. Journal of Clinical Psychiatry 57 (Suppl. 4): 19-25.
8. De Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM (1988). Neurochemical and autonomic pharmacological prophile of the 6-aza-analogue of mianserine, Org 3770 and its enantiomers. Neuropharmacology 27, 399-408.
9. De Boer TH, Nefkens F, Van Velvoirt A (1996). Differences in modulation of noradrenergic and serotonergic transmission by the alpha-2 adrenoceptor antagonists, mirtazapine, mianserin and idazoxan. Journal of Pharmacology and Experimental Therapeutics 277, 852-860.
10. De Montis MG, Gambarana C, Ghiglieri O, Tagliamonte A (1995). Reversal of stable behavioural modifications through NMDA receptor inhibition in rats. Behavioural Pharmacology 6, 562-567.
11. Doherty MD, Pickel VM (2001). Targeting of serotonin 1A receptors to dopaminergic neurons within the parabrachial subdivision of the ventral tegmental area in rat brain. Journal of Comparative Neurology 433, 390-400.
12. Eddy NB, Leimbach D (1953). Synthetic analgesics. II Diethinylbutenyl-and dithienylbutylamines. Journal of Pharmacology and Experimental Therapeutics 107, 385-393.
13. Fawcett J, Barkin RL (1999). Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. Journal of Affective Disorders 51, 267-85.
14. Gambarana C, Ghiglieri O, Taddei I, Tagliamonte A, De Montis MG (1995a). Imipramine and fluoxetine prevent the stress-induced escape deficits in rats through a distinct mechanism of action. Behavioural Pharmacology 6, 66-73.
15. 1 dopamine receptors in mediating the antidepressant effect of imipramine. Pharmacology, Biochemistry, and Behavior 50, 147-151.
16. Gambarana C, Ghiglieri O, Tolu P, De Montis MG, Giachetti D, Bombardelli E, Tagliamonte A (1999). Efficacy of an Hypericum perforatum (St. John's Wort) extract in preventing and reverting a condition of escape deficit in rats. Neuropsychopharmacology 21, 247-257.
17. Gambarana C, Scheggi S, Tagliamonte A, Tolu P, De Montis MG (2001). Animal models for the study of antidepressant activity. Brain Research Protocols 7, 11-20.
18. Ghiglieri O, Gambarana C, Scheggi S, Tagliamonte A, Willner P, De Montis MG (1997). Palatable food induces an appetitive behaviour in satiated rats which can be inhibited by chronic stress. Behavioural Pharmacology 8, 619-628.
19. Grappi S, Nanni G, Leggio B, Rauggi R, Scheggi S, Masi F, Gambarana C (2003). The efficacy of reboxetine in preventing and reverting a condition of escape deficit in rats. Biological Psychiatry 53, 890-898.
20. 2-adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. Journal of Pharmacology and Experimental Therapeutics 277, 861-871.
21. Haddjeri N, Blier P, De Montigny C (1998). Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission. Journal of Affective Disorders 51, 255-266.
22. Laakmann G, Schule C, Baghai T, Waldvogel E (1999). Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology 24, 769-784.
23. Lejeune F, Millan MJ (1998). Induction of burst firing in ventral tegmental area dopaminergic neurons by activation of serotonin (5-HT)1A receptors: WAY 100,635-reversible actions of the highly selective ligands, flesinoxan and S15535. Synapse 30, 172-180.
24. Meloni D, Gambarana C, De Montis MG, Dal Prá P, Taddei I, Tagliamonte A (1993). Dizocilpine antagonizes the effect of chronic imipramine on learned helplessness in rats. Pharmacology, Biochemistry, and Behavior 46, 423-426.
25. Montgomery SA (1995). Safety of mirtazapine: a review. International Clinical Psychopharmacology 10 (Suppl. 4): 37-45.
26. Overmier JB, Seligman MEP (1967). Effects of inescapable shock upon subsequent escape and avoidance learning. Journal of Comparative Physiology and Psychology 63, 23-33.
27. Panconi E, Roux J, Altenbaumer M, Hampe S, Porsolt RD (1993). MK-801 and enantiomers: potential antidepressants or false positives in classical screening models? Pharmacology, Biochemistry, and Behavior 46, 15-20.
28. Paul IA, Skolnick P (2003). Glutamate and depression: clinical and preclinical studies. Annals of the New York Academy of Sciences 1003, 250-272.
29. Prisco S, Pagannone S, Esposito E (1994). Serotonin-dopamine interaction in the rat ventral tegmental area: an electrophysiological study in vivo. Journal of Pharmacology and Experimental Therapeutics 271, 83-90.
30. Puzantian T (1998). Mirtazapine, an antidepressant. American Journal of Health-System Pharmacy 55, 44-49.
31. Schule C, Baghai T, Bidlingmaier M, Strasburger C, Laakman G (2002). Endocrinological effects of mirtazapine in healthy volunteers. Progress in Neuropsycopharmacology and Biological Psychiatry 26, 1253-1261.
32. Sherman AD, Sacquitne JL, Petty F (1982). Specificity of the learned helplessness model of depression. Pharmacology, Biochemistry, and Behavior 16, 449-454.
33. Thompson C (1999). Mirtazapine versus selective serotonin reuptake inhibitors. Journal of Clinical Psychiatry 60 (Suppl. 17), 18-22.
34. Willner P (1995). Animal models of depression: validity and applications. Advances in Biochemistry and Psychopharmacology 49, 19-41.